若叠加2024年累计30亿元的回购注销,药明康德在16个月内已宣布回购总额达50亿元,堪称A股“回购狂魔”。2025年4月8日,无锡药明康德新药开发股份有限公司(603259.SH,02359.HK,以下简称“药明康德”)发布公告称,因A股股价连续20个交易日累计跌幅超20%,公司计划启动2025年第二次股份回购,拟投入资金10亿元,回购价格上限为97.24元/股,并全部注销以减少注册资本。4月9...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.